Effect of hemodialysis and hemofiltration on plasma C.E.R.A. concentrations

摘要: C.E.R.A., a continuous erythropoietin receptor activator, is long-acting erythropoiesis-stimulating agent approved for the treatment of anemia in patients with chronic kidney disease. Although large molecular weight and carbohydrate chain make it unlikely that C.E.R.A. could be removed during hemodialysis or hemofiltration, no such data have been published. In vitro studies were performed to assess removal using both low-flux high-flux membranes parameters very similar those used clinical practice. Clinical pharmacokinetic plasma concentrations undergoing also following subcutaneous injection studies, not significantly different from baseline values primed blood reservoir over 4-hour period (P = 0.12). obtained venous end hemofilter increased proportionally total protein concentrations, reflecting consequence hemoconcentration suggesting C.E.R.A proteins retained by hemofiltration degree. These showed was simulated either via transmembrane transport adsorption membrane. The results corroborated data, which detectable changes dialyzers. suggest can administered at any time without appreciable loss extracorporeal circuit.